{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:46:57Z","timestamp":1787021217057,"version":"build-2736575974"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01215-0","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T23:13:11Z","timestamp":1775171591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Virtual Bioequivalence Assessment of Long-Acting Injectable Suspensions Using PBPK Modeling: Part 2. Type I Error and Safe Space Analyses"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-5832","authenticated-orcid":false,"given":"Natalie M.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-0194","authenticated-orcid":false,"given":"Masoud","family":"Jamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8757-2412","authenticated-orcid":false,"given":"Khondoker","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-8528","authenticated-orcid":false,"given":"Eleftheria","family":"Tsakalozou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7537-9615","authenticated-orcid":false,"given":"Mark","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5206-1920","authenticated-orcid":false,"given":"Kairui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4154-0391","authenticated-orcid":false,"given":"Frederic Y.","family":"Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"publisher","unstructured":"Morris NM, Djehizian A, Mittapally N, Chaitanya Telaprolu K, Holland B, McNally K, et al. Virtual bioequivalence assessment of long-acting injectable suspensions using PBPK modeling: part 1. Impact of particle size on formulation variability. AAPS J. 2026. https:\/\/doi.org\/10.1208\/s12248-026-01213-2.","DOI":"10.1208\/s12248-026-01213-2"},{"issue":"10","key":"1215_CR2","first-page":"1734","volume":"13","author":"X Chen","year":"2024","unstructured":"Chen X, Nyberg HB, Donnelly M, Zhao L, Fang L, Karlsson MO, et al. Development and comparison of model\u2010integrated evidence approaches for bioequivalence studies with pharmacokinetic end points. CPT: Pharmacometrics and Systems Pharmacology. 2024;13(10):1734\u201347.","journal-title":"CPT: Pharmacometrics and Systems Pharmacology"},{"key":"1215_CR3","unstructured":"US FDA center for drug evaluation and research. The use of physiologically based pharmacokinetic analyses - biopharmaceutics applications for oral drug product development, manufacturing changes, and controls guidance for industry [Internet]. US FDA; 2020. Available from: https:\/\/www.fda.gov\/media\/142500\/download. Accessed 21 Dec 2024."},{"issue":"30","key":"1215_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1404619","volume":"15","author":"FY Bois","year":"2024","unstructured":"Bois FY, Brochot C. A Bayesian framework for virtual comparative trials and bioequivalence assessments. Front Pharmacol. 2024;15(30):1404619.","journal-title":"Front Pharmacol"},{"key":"1215_CR5","unstructured":"Kirsch A. An introduction to the mathematical theory of inverse problems [Internet]. 3rd ed. In: Applied Mathematical Sciences; vol. 120. Cham: Springer International Publishing; 2021. Available from: http:\/\/link.springer.com\/10.1007\/978-3-030-63343-1. Accessed 8 Mar 2025."},{"key":"1215_CR6","unstructured":"US FDA center for drug evaluation and research. statistical approaches to establishing bioequivalence [Internet]. US FDA; 2001. Available from: https:\/\/www.fda.gov\/media\/70958\/download. Accessed 21 Dec 2024."},{"issue":"4","key":"1215_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404\u201313.","journal-title":"Biometrika"},{"key":"1215_CR8","unstructured":"R Development Core Team. R: A language and environment for statistical computing (R foundation for statistical computing, Vienna, Austria, http:\/\/www.R-project.org) [Internet]. Vienna, Austria: R foundation for statistical computing; 2013. Available from: http:\/\/www.R-project.org. Accessed 21 Dec 2024."},{"key":"1215_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106296","volume":"179","author":"P Gajjar","year":"2022","unstructured":"Gajjar P, Dickinson J, Dickinson H, Ruston L, Mistry HB, Patterson C, et al. Determining bioequivalence possibilities of long acting injectables through population PK modelling. Eur J Pharm Sci. 2022;179:106296.","journal-title":"Eur J Pharm Sci"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01215-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01215-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01215-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:59:51Z","timestamp":1779803991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01215-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01215-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Some of the authors are employees and potential shareholders of Certara Inc. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement, by FDA\/HHS, or the U.S. Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"86"}}